AB&B Bio-Tech-B Maintains Stable Share Capital in June; Public Float Remains Compliant

Bulletin Express07-06 16:58

AB&B Bio-Tech-B (02627.HK) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 July 2026, covering the month ended 30 June 2026. The filing indicates no changes in authorised, issued or treasury shares during the period.

The company’s authorised share capital stayed at RMB 393.44 million, comprising 393.44 million ordinary shares with a par value of RMB 1 each. This includes 296.36 million H shares listed on the Stock Exchange and 97.08 million unlisted domestic shares.

Issued share capital mirrored the authorised structure, with 296.36 million H shares and 97.08 million domestic shares outstanding—unchanged from the prior month. The issuer held no treasury shares.

AB&B Bio-Tech-B confirmed that, as of 30 June 2026, it satisfied the Main Board’s minimum 25 percent public-float requirement for its H-share class.

The company reported no outstanding share options, warrants, convertible securities or other agreements that could dilute existing equity. The filing was signed by Executive Director Li Runxiang, affirming compliance with all applicable listing and regulatory obligations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151127318?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151127318","market":"hk","top_or_hot":-1,"title":"AB&B Bio-Tech-B Maintains Stable Share Capital in June; Public Float Remains Compliant","media":"Bulletin Express","content":"<p>AB&B Bio-Tech-B (02627.HK) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 July 2026, covering the month ended 30 June 2026. The filing indicates no changes in authorised, issued or treasury shares during the period.</p>\n<p>The company’s authorised share capital stayed at RMB 393.44 million, comprising 393.44 million ordinary shares with a par value of RMB 1 each. This includes 296.36 million H shares listed on the Stock Exchange and 97.08 million unlisted domestic shares.</p>\n<p>Issued share capital mirrored the authorised structure, with 296.36 million H shares and 97.08 million domestic shares outstanding—unchanged from the prior month. The issuer held no treasury shares.</p>\n<p>AB&B Bio-Tech-B confirmed that, as of 30 June 2026, it satisfied the Main Board’s minimum 25 percent public-float requirement for its H-share class.</p>\n<p>The company reported no outstanding share options, warrants, convertible securities or other agreements that could dilute existing equity. The filing was signed by Executive Director Li Runxiang, affirming compliance with all applicable listing and regulatory obligations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AB&B Bio-Tech-B Maintains Stable Share Capital in June; Public Float Remains Compliant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAB&B Bio-Tech-B Maintains Stable Share Capital in June; Public Float Remains Compliant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-06 16:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AB&B Bio-Tech-B (02627.HK) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 July 2026, covering the month ended 30 June 2026. The filing indicates no changes in authorised, issued or treasury shares during the period.</p>\n<p>The company’s authorised share capital stayed at RMB 393.44 million, comprising 393.44 million ordinary shares with a par value of RMB 1 each. This includes 296.36 million H shares listed on the Stock Exchange and 97.08 million unlisted domestic shares.</p>\n<p>Issued share capital mirrored the authorised structure, with 296.36 million H shares and 97.08 million domestic shares outstanding—unchanged from the prior month. The issuer held no treasury shares.</p>\n<p>AB&B Bio-Tech-B confirmed that, as of 30 June 2026, it satisfied the Main Board’s minimum 25 percent public-float requirement for its H-share class.</p>\n<p>The company reported no outstanding share options, warrants, convertible securities or other agreements that could dilute existing equity. The filing was signed by Executive Director Li Runxiang, affirming compliance with all applicable listing and regulatory obligations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1151127318","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151127318","pubTimestamp":1783328288,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"AB&B Bio-Tech-B (02627.HK) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 July 2026, covering the month ended 30 June 2026. The filing indicates no...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"AB&B Bio-Tech-B 6月股本保持稳定；公众持股量保持合规","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":1},"content_text":"AB&B Bio-Tech-B (02627.HK) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 July 2026, covering the month ended 30 June 2026. The filing indicates no changes in authorised, issued or treasury shares during the period.\nThe company’s authorised share capital stayed at RMB 393.44 million, comprising 393.44 million ordinary shares with a par value of RMB 1 each. This includes 296.36 million H shares listed on the Stock Exchange and 97.08 million unlisted domestic shares.\nIssued share capital mirrored the authorised structure, with 296.36 million H shares and 97.08 million domestic shares outstanding—unchanged from the prior month. The issuer held no treasury shares.\nAB&B Bio-Tech-B confirmed that, as of 30 June 2026, it satisfied the Main Board’s minimum 25 percent public-float requirement for its H-share class.\nThe company reported no outstanding share options, warrants, convertible securities or other agreements that could dilute existing equity. The filing was signed by Executive Director Li Runxiang, affirming compliance with all applicable listing and regulatory obligations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151127318","isCrawlerRequest":true}